PRAX (Praxis Medicines) Forward P/E Multiple

PRAX (Praxis Precision Medicines) - company brandmark

The resilience of Praxis Precision Medicines (PRAX) is based on the commercialization of therapies for epilepsy and Parkinson's disease. The company's estimated forward P/E reflects market sentiment, with the current level sitting around 0.00. High authority in neuromedicine confirms physician confidence in precision treatment methods, while compliance with bio-laboratory regulations and digitalization minimize the business's environmental footprint.

praxismedicines.com - PRAX Price to Future Earnings Ratio (period 07/04/2022 - 11/15/2026)

Analytical breakdowns and data insights for company Praxis Precision Medicines, Inc. (PRAX)

- stock value and consensus price forecast:
Signature product of praxismedicines.com

Praxis Precision Medicines (PRAX) is investing in costly R&D for epilepsy treatments, which temporarily precludes operating profit. When analyzing the company's forward P/E ratio, an investor assesses the market price of the stock relative to the expected earnings per share. This multiple measures the market's willingness to pay a premium for the future success of the pipeline. A decline in this indicator may signal either an undervaluation or an increase in the risks of revenue degradation.

Competitor analysis for Praxis Precision Medicines

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|anavex.com - Forward P/E Multiple|Future Price to Earnings Multiple CBLL (CeriBell, Inc.)|PRTA: Forward P/E Multiple|Price to Future Earnings Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Forward P/E Multiple|omeros.com - Price to Expected Earnings Ratio|Future Price to Earnings Neurogene (NGNE)|Market Cap to Projected Earnings AC Immune SA|Forward P/E Multiple VYGR (voyagertherapeutics.com)|Forward P/E Multiple Neumora NMRA|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)